Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of MAPK-ERK1/2 signal channel inhibitor to preparation of double-minute medicine for removing or inhibiting tumor cells

A tumor cell and inhibitor technology, applied in antitumor drugs, drug combinations, pharmaceutical formulations, etc., can solve the problems of short half-life of hydroxyurea, high dose, and lack of strong tumor specificity, so as to improve specificity and reduce malignant degree of effect

Active Publication Date: 2012-11-21
HARBIN MEDICAL UNIVERSITY
View PDF3 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The disadvantage is that hydroxyurea will also be used in tumor treatment in clinical practice, but it does not have strong specificity for tumors. The half-life of hydroxyurea is short, and high doses are prone to rapid tolerance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of MAPK-ERK1/2 signal channel inhibitor to preparation of double-minute medicine for removing or inhibiting tumor cells
  • Application of MAPK-ERK1/2 signal channel inhibitor to preparation of double-minute medicine for removing or inhibiting tumor cells
  • Application of MAPK-ERK1/2 signal channel inhibitor to preparation of double-minute medicine for removing or inhibiting tumor cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0056] Example 1 Effect of MAPK-ERK1 / 2 signaling pathway inhibitors on double microsomes in tumor cells

[0057] 1. Select malignant tumor cells containing double microsomes as research objects

[0058] Malignant tumor cell lines containing double microsomes were selected from ATCC as research objects, including human ovarian cancer cell line UACC-1598, human colorectal adenocarcinoma cell line NCI-H716, human colon adenocarcinoma cell line NCI-H508, human neuronal carcinoma cell line Ectodermal tumor cell line SK-PN-DW, human myeloid leukemia cell line HL-60 and human gastric adenocarcinoma cell line NCI-N87.

[0059] In order to understand the situation of each cell line containing double minors, the metaphase chromosome samples of various cell lines were firstly prepared. Add colchicine at a final concentration of 0.01 μg / mL to UACC-1598, NCI-H716, NCI-H508, SK-PN-DW, HL-60 and NCI-N87 cells in the logarithmic growth phase, and continue to culture at 37°C 1-2h, blow the c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of a MAPK-ERK1 / 2 signal channel inhibitor to the preparation of double-minute medicine for removing or inhibiting tumor cells and belongs to the technical field of tumor biological treatment. By aiming at the poor tumor treatment effect in the prior art, a target biological treatment strategy of tumors containing double minutes is further provided, the fact that double minutes in malignant cells and the ERK1 / 2 protein kinase activity have the close relationship obtained through research is used as the theoretical basis, and the application disclosed by the invention is specially provided by aiming at the ERK1 / 2 protein kinase continuous phosphorylation double-minute tumor type caused by the MAPK-ERK1 / 2 signal transduction channel abnormity. The method disclosed by the invention has the advantages that the tumor treatment specificity is improved, the existing treatment scheme is improved, and on the other hand, the invention also provides a strategy for double-minute targeting treatment.

Description

technical field [0001] The present invention relates to a medicine capable of removing or inhibiting double microsomes in tumor cells, in particular to a medicine capable of removing or inhibiting double microsomes in malignant tumor cells continuously activated in the MAPK-ERK1 / 2 signal transduction pathway. The invention belongs to the technical field of tumor biotherapy. Background technique [0002] Double minutes or double minute chromosomes (DMs) are the main cytogenetic markers of gene amplification. They are small, paired chromatin bodies without centrioles located in extrachromosomal cells. They are extrachromosomal A major form of genetic units. [0003] In 1962, this extrachromosomal microbody was first found in some malignant tumor cells, exudates and metastatic cells of lung cancer pleural effusion. At present, double microsomes have been detected in various hematological tumors such as leukemia and malignant lymphoma, as well as solid tumors such as lung canc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/277A61K31/352A61P35/00
Inventor 傅松滨孙文靖于旸金焰孟祥宁白静全超关荣伟
Owner HARBIN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com